Spectral Medical Inc.EDT.TO
Health Care · Health Care Equipment & Services · TSX · Canada
Spectral Medical Inc. is a late-stage theranostic company focused on therapeutic solutions for sepsis and septic shock. Its lead product, Toraymyxin (PMX), is a hemoperfusion device approved in Japan and Europe that removes endotoxin from the bloodstream, guided by the company's Endotoxin Activity Assay (EAA), the only FDA-cleared diagnostic for sepsis risk assessment.
Key ratios
FCF / Sales
-398.0%TTM
2025
-398.0%2024
-386.9%2023
-682.5%
ROA
-122.3%TTM
2025
-122.3%2024
-143.3%2023
-81.0%
Recent news
Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA
Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Spectral Medical Announces U.S. FDA Filing of PMA Application for PMX
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine
Track EDT.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer